摘要
阿尔茨海默病(AD)是老年性痴呆症中最常见的形式,其发病机制仍不清楚,但β淀粉样蛋白(Aβ)被认为是引起AD发病的重要原因,然而其引发AD的病理机制同样存在多种争议。最近研究显示,髓系细胞触发受体(TREM2)在AD病理进程中扮演重要角色,其不仅可以作为Aβ内化的重要受体,还可能成为生物学诊断标志物和治疗靶点,阐明TREM2的结构和功能,将为AD的防治提供重要的思路。本文将从TREM2的结构、TREM2对小胶质细胞功能的影响、TREM2在AD中的病理学作用以及靶向TREM2治疗AD的现状进行系统性综述,这些总结将为AD的基础研究提供具有价值的参考。
Alzheimer′s disease(AD)is the most common form of senile dementia,and its pathogenesis is still un-clear.Whileβ-amyloid(Aβ)is considered an important cause of AD,the pathological mechanism of Aβinducing AD is subject to various controversies.Recent studies have shown that the myeloid cell trigger receptor(TREM2)plays an impor-tant role in the pathological process of AD,and it can not only serve as an important receptor for the internalization of Aβbut also become a biological diagnostic biomarker and therapeutic target.Hence,elucidating the structure and function of TREM2 will provide important ideas for the prevention and treatment of AD.This article will provide a systematic review of the structure of TREM2,its impact on microglial cell function,its pathological role in AD,and the current status of target-ed TREM2 therapy for AD.These summaries will provide valuable references for basic research on AD.
作者
代玉婷
石镜明
DAI Yuting;SHI Jingming(Brain Injury and Repair Research Laboratory in High Altitude Environment,School of Medicine,Xizang Minzu University,Xianyang 712082,China)
出处
《中山大学学报(医学科学版)》
CAS
CSCD
北大核心
2024年第3期344-353,共10页
Journal of Sun Yat-Sen University:Medical Sciences
基金
国家自然科学基金(32160215,82360368)
西藏民族大学“青年学人培育计划”资助项目(23MDX03)。